<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00281203</url>
  </required_header>
  <id_info>
    <org_study_id>1327</org_study_id>
    <secondary_id>R01HL082480</secondary_id>
    <nct_id>NCT00281203</nct_id>
  </id_info>
  <brief_title>Comparison of Alveolar Macrophages in Healthy Individuals Versus Individuals With COPD</brief_title>
  <official_title>Innate and Adaptive Immunity in COPD Exacerbations: Bronchoscopies on Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Michigan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Michigan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study group forms the normal subject control group in an experiment designed to&#xD;
      determine whether the alveolar macrophages (AMø) of patients with chronic obstructive&#xD;
      pulmonary disease (COPD) show abnormal responsiveness to bacterial and viral products.&#xD;
      Specifically, the study will determine the dose-response characteristics of AMø for&#xD;
      production of interleukin (IL)-6, IL-18, and IL-23 (pro-inflammatory cytokines) on&#xD;
      stimulation by purified lipopolysaccharide, a synthetic lipopeptide (PAM3-Cys), or poly I:C.&#xD;
      These stimuli mimic the response to Gram-negative bacteria, Gram-positive bacteria, and RNA&#xD;
      viruses, respectively. Results of the AMø from these healthy volunteers will be compared with&#xD;
      AMø of COPD patients and smokers (or ex-smokers) with normal pulmonary function; those&#xD;
      samples are being obtained during clinically indicated bronchoscopies under a separate&#xD;
      consent form.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      BACKGROUND:&#xD;
&#xD;
      COPD is one of the most pressing healthcare problems facing our nation. Acute exacerbations&#xD;
      of COPD (AE-COPD) are responsible for the bulk of healthcare costs, and much of the morbidity&#xD;
      and decline in health status among individuals with this common disease. The lack of accepted&#xD;
      animal models of AE-COPD necessitates novel approaches using human samples. Advances in the&#xD;
      understanding of the pathogenesis have been slowed, in part, due to controversy as to how&#xD;
      exacerbations should be defined. The prevailing paradigm has defined AE-COPD as event-based.&#xD;
      Such definitions clearly identify groups of patients with accelerated loss of pulmonary&#xD;
      function and increased mortality. However, limited data show that symptom-based definitions&#xD;
      of AE-COPD also capture episodes inducing significant morbidity and functional decline, and&#xD;
      hence of concern to patients. Fundamental mechanisms are lacking to explain AE-COPD defined&#xD;
      by either means.&#xD;
&#xD;
      Controversy also surrounds triggers of AE-COPD. Bacteria and viruses are involved in some&#xD;
      episodes, but the relative importance of each is intertwined with disputes over the&#xD;
      definition of AE-COPD. Progress at linking specific pathogens to molecular pathogenesis has&#xD;
      been slow, both due to their diversity, and to the high rates of bacterial colonization of&#xD;
      patients with COPD, even in the stable state. Moreover, in many AE-COPD cases, no pathogen&#xD;
      can be identified. Without negating the value of analyzing infections with specific species&#xD;
      of pathogens, it appears that progress in molecular pathogenesis could be accelerated by&#xD;
      focusing on unifying features of the pulmonary immune response during AE-COPD.&#xD;
&#xD;
      DESIGN NARRATIVE:&#xD;
&#xD;
      Bronchoscopies will be performed on healthy volunteers. Subjects are reimbursed $30 for the&#xD;
      initial visit and $150 at completion of the bronchoscopy to help defray travel expenses and&#xD;
      for the time spent participating as a volunteer.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2005</start_date>
  <completion_date type="Actual">July 2010</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>alveolar macrophage functions in vitro</measure>
    <time_frame>day of bronchoscopy</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">32</enrollment>
  <condition>Pulmonary Disease, Chronic Obstructive</condition>
  <condition>Lung Diseases, Obstructive</condition>
  <arm_group>
    <arm_group_label>healthy smokers</arm_group_label>
    <description>Must be free of serious diseases that might make it dangerous to undergo bronchoscopy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>blood drawing</intervention_name>
    <description>blood will be drawn on the entry visit and will starting the intravenous (IV) line on the day of bronchoscopy</description>
    <arm_group_label>healthy smokers</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>fiberoptic bronchoscopy</intervention_name>
    <description>A flexible instrument will be passed through the mouth and into the lungs. Portions of the lungs will be washed, by injecting and immediately suctioning out a small amount of fluid. The entire return will be used for research purposes, and no results will be reported to the participant. Bronchoscopy is performed once.</description>
    <arm_group_label>healthy smokers</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Healthy volunteers&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Healthy individuals with normal pulmonary function as defined by AmericanThoracic&#xD;
             Society criteria (entry spirometry)&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Unstable cardiovascular disease&#xD;
&#xD;
          -  Other systemic disease in which survival of more than 2 years is unlikely&#xD;
&#xD;
          -  Mental incompetence or active psychiatric illness&#xD;
&#xD;
          -  Currently taking more than 20 mg/day of Prednisone&#xD;
&#xD;
          -  Participation in another experimental protocol within 6 weeks of study entry&#xD;
&#xD;
          -  Asthma&#xD;
&#xD;
          -  Cystic fibrosis&#xD;
&#xD;
          -  Clinically significant bronchiectasis&#xD;
&#xD;
          -  Lung cancer&#xD;
&#xD;
          -  Other inflammatory or fibrotic lung disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey L. Curtis</last_name>
    <role>Study Chair</role>
    <affiliation>University of Michigan at Ann Arbor</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Michigan at Ann Arbor</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.copdfoundation.org/</url>
    <description>COPD Foundation</description>
  </link>
  <link>
    <url>https://www.umms.med.umich.edu/umclinicalstudies/</url>
    <description>University of Michigan research site for participants</description>
  </link>
  <link>
    <url>http://www.med.umich.edu/intmed/pulmonary/edu/mtp.htm</url>
    <description>Training Grant in Lung Diseases</description>
  </link>
  <link>
    <url>http://www.med.umich.edu/immprog/</url>
    <description>Graduate Program in Immunology</description>
  </link>
  <link>
    <url>http://umhsheadlines.org/10/progress-being-made-on-joint-initiatives-with-peking-university-2/</url>
    <description>University of Michigan-Peking University Joint Initiative for Clinical &amp; Translational Research</description>
  </link>
  <reference>
    <citation>Freeman CM, Curtis JL, Chensue SW. CC chemokine receptor 5 and CXC chemokine receptor 6 expression by lung CD8+ cells correlates with chronic obstructive pulmonary disease severity. Am J Pathol. 2007 Sep;171(3):767-76. Epub 2007 Jul 19.</citation>
    <PMID>17640964</PMID>
  </reference>
  <reference>
    <citation>Freeman CM, Han MK, Martinez FJ, Murray S, Liu LX, Chensue SW, Polak TJ, Sonstein J, Todt JC, Ames TM, Arenberg DA, Meldrum CA, Getty C, McCloskey L, Curtis JL. Cytotoxic potential of lung CD8(+) T cells increases with chronic obstructive pulmonary disease severity and with in vitro stimulation by IL-18 or IL-15. J Immunol. 2010 Jun 1;184(11):6504-13. doi: 10.4049/jimmunol.1000006. Epub 2010 Apr 28.</citation>
    <PMID>20427767</PMID>
  </reference>
  <reference>
    <citation>Freeman CM, Martinez FJ, Han MK, Ames TM, Chensue SW, Todt JC, Arenberg DA, Meldrum CA, Getty C, McCloskey L, Curtis JL. Lung dendritic cell expression of maturation molecules increases with worsening chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2009 Dec 15;180(12):1179-88. doi: 10.1164/rccm.200904-0552OC. Epub 2009 Sep 3.</citation>
    <PMID>19729666</PMID>
  </reference>
  <reference>
    <citation>Han MK, Agusti A, Calverley PM, Celli BR, Criner G, Curtis JL, Fabbri LM, Goldin JG, Jones PW, Macnee W, Make BJ, Rabe KF, Rennard SI, Sciurba FC, Silverman EK, Vestbo J, Washko GR, Wouters EF, Martinez FJ. Chronic obstructive pulmonary disease phenotypes: the future of COPD. Am J Respir Crit Care Med. 2010 Sep 1;182(5):598-604. doi: 10.1164/rccm.200912-1843CC. Epub 2010 Jun 3.</citation>
    <PMID>20522794</PMID>
  </reference>
  <reference>
    <citation>Curtis JL, Todt JC, Hu B, Osterholzer JJ, Freeman CM. Tyro3 receptor tyrosine kinases in the heterogeneity of apoptotic cell uptake. Front Biosci (Landmark Ed). 2009 Jan 1;14:2631-46. Review.</citation>
    <PMID>19273223</PMID>
  </reference>
  <reference>
    <citation>Curtis JL, Freeman CM, Hogg JC. The immunopathogenesis of chronic obstructive pulmonary disease: insights from recent research. Proc Am Thorac Soc. 2007 Oct 1;4(7):512-21. Review.</citation>
    <PMID>17878463</PMID>
  </reference>
  <results_reference>
    <citation>Erb-Downward JR, Thompson DL, Han MK, Freeman CM, McCloskey L, Schmidt LA, Young VB, Toews GB, Curtis JL, Sundaram B, Martinez FJ, Huffnagle GB. Analysis of the lung microbiome in the &quot;healthy&quot; smoker and in COPD. PLoS One. 2011 Feb 22;6(2):e16384. doi: 10.1371/journal.pone.0016384.</citation>
    <PMID>21364979</PMID>
  </results_reference>
  <results_reference>
    <citation>Punturieri A, Copper P, Polak T, Christensen PJ, Curtis JL. Conserved nontypeable Haemophilus influenzae-derived TLR2-binding lipopeptides synergize with IFN-beta to increase cytokine production by resident murine and human alveolar macrophages. J Immunol. 2006 Jul 1;177(1):673-80.</citation>
    <PMID>16785566</PMID>
  </results_reference>
  <verification_date>July 2013</verification_date>
  <study_first_submitted>January 20, 2006</study_first_submitted>
  <study_first_submitted_qc>January 20, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 24, 2006</study_first_posted>
  <last_update_submitted>July 15, 2013</last_update_submitted>
  <last_update_submitted_qc>July 15, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 16, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Michigan</investigator_affiliation>
    <investigator_full_name>Jeffrey L. Curtis</investigator_full_name>
    <investigator_title>Professor of Internal Medicine (Pulmonary &amp; Critical Care Medicine)</investigator_title>
  </responsible_party>
  <keyword>Chronic Obstructive Pulmonary Disease</keyword>
  <keyword>COPD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

